Chester County News and Community Website
Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), headquartered in West Chester, PA, is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. For more information, visit www.verrica.com.
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported a new analysis showing patients treated with YCANTH cleared molluscum contagiosum at about four times the rate of those receiving …
Verrica Analysis Shows Faster Clearance With YCANTH Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) will present new Phase 3 analyses showing its FDA-approved YCANTH treatment produced higher molluscum contagiosum clearance rates than vehicle regardless of …
Verrica Data Show YCANTH Response Across Disease Duration Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) will present its dermatology drug portfolio to investors Monday at the H.C. Wainwright 28th Annual Global Investment Conference in New York …
Verrica Puts Investor Focus on Dermatology Pipeline Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has completed enrollment in the first pivotal Phase 3 trial of YCANTH for common warts and passed an interim statistical review …
Verrica Advances Wart Drug Expansion as Phase 3 Trial Fills Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported a $13.2 million second-quarter loss as total revenue fell sharply from a year earlier despite record demand and higher U.S. …
Verrica Revenue Falls Despite Record YCANTH Demand Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) will report second-quarter 2026 financial results on Aug. 6 and provide investors with a corporate update as the dermatology company continues …
Verrica Schedules Aug. 6 Earnings Call With Corporate Update Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has granted Medomie Pharma Ltd. exclusive rights to seek regulatory approval and commercialize its skin disease treatment YCANTH in Israel, expanding …
Verrica Expands YCANTH Rights to Israel in Licensing Deal Read More WEST CHESTER, PA — Verrica Pharmaceuticals (Nasdaq: VRCA) has dosed the first U.S. patient in a second Phase 3 clinical trial evaluating YCANTH for common warts, expanding a late-stage development …
Verrica Advances Wart Treatment Program With Phase 3 Trial Expansion Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported higher first-quarter revenue and accelerating demand for its YCANTH treatment as the company advances late-stage clinical trials that could significantly …
Verrica Expands YCANTH Sales as Wart Trials Advance Read More WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) said it will present Phase 2 exploratory data on its investigational skin cancer treatment VP-315 at the 2026 Society for Investigative …
Verrica to Present Phase 2 Data on Skin Cancer Therapy at SID Meeting Read More